<DOC>
	<DOC>NCT02399813</DOC>
	<brief_summary>This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 subjects, respectively with persistent/recurrent, loco-regional or metastatic SCCA of the anorectal canal that have received at least 1 regimen for the treatment of advanced disease</brief_summary>
	<brief_title>Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<criteria>Must have cancer of the anal canal OR rectal cancer. Must have metastatic disease or persistent/recurrent locoregional disease Prior Therapy: may have received &lt;2 regimens for disease in the metastatic setting. At least one line of therapy. Be willing and able to provide written informed consent for the trial. Be â‰¥18 years of age on day of signing informed consent. Have measurable disease based on RECIST 1.1 Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Demonstrate adequate organ function as defined in protocol. Females cannot be pregnant or breastfeeding and must take two methods of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>